Parma, 23 November 2016

# EFSA Info session - technical meeting with stakeholders on supplementary guidance for allergenicity assessment of GM plants

23 November 2016

Location: EFSA, Meeting rooms (07/08), Parma (Italy)

## Agenda

| **23 November 2016** | | |
|---|---|---|
| **Time** | **Subject** | **Speaker** |
| 8:00-8:30 | Registration | |
| 8:30-8:45 | Welcome and scope of the meeting | **E. Waigmann**, Head, EFSA GMO Unit |
| 8:45–9:00 | Introduction to the EFSA guidance document on allergenicity assessment of GM plants | **J.M. Wal**, GMO Panel, Allergenicity WG/ INRA, France |
| 9:00–9:20 | *In vitro* protein digestibility test for allergenicity assessment – EFSA proposal | **C. Mills**, Allergenicity WG/ University of Manchester, UK |
| 9:20–09:35 | *In vitro* digestibility testing – Infogest | **A. Mackie**, University of Leeds, UK |
| 9:35-9:45<br>9:45-9:55 | *In vitro* protein digestibility testing – feedback from stakeholders after public consultation | **R. van Ree**, University of Amsterdam/ representative: ILSI-HESI;<br>**F. Jacquemart**, GIET (Groupe International d'Études Transdisciplinaires) |
| 9:55-10:15 | *Coffee break* | |
| 10:15-11:10 | *In vitro* protein digestibility testing – plenary discussion | |
| 11:10-11:30 | Endogenous allergenicity – EFSA proposal | **R. Selb**, EFSA GMO Unit |

| | | |
|---|---|---|
| 11:30–11:45 | Endogenous allergenicity – clinical aspects | **P. Eigenmann**, Allergenicity WG/ University of Geneva, Switzerland |
| 11:45-11:55<br>11:55–12:05 | Endogenous allergenicity – feedback from stakeholders after public consultation | **R. Crevel**, Unilever/ Focus Group representative: FoodDrink Europe;<br>**S. Schnadt**, Focus Group patient's representative: DAAB (German Allergy and Asthma association) |
| 12:05-13:05 | *Lunch break* | |
| 13:05–14:00 | Endogenous allergenicity – plenary discussion | |
| 14:00–14:20 | Non – IgE adverse immune reactions (celiac disease)– EFSA proposal | **F. Koning**, Allergenicity WG/ Leiden University, The Netherlands |
| 14:20–14:35 | Non – IgE adverse immune reactions (celiac disease) – *in silico* tools | **P. Rougé**, Université Paul Sabatier, France/ Focus Group representative France |
| 14:35-14:55 | *Coffee break* | |
| 14:55-15:05<br>15:05-15:15 | Non – IgE adverse immune reactions (celiac disease) – feedback from stakeholders after public consultation | **Kathryn Miller**, Celiac UK/ patients' representative;<br>**Andre Silvanovich**, Monsanto/ industry representative |
| 15:15–16:10 | Non -IgE adverse immune reactions (celiac disease) – plenary discussion | |
| 16:10–16:30 | Concluding remarks | **A. Fernandez Dumont**, EFSA GMO Unit |